The International Society of Gastrointestinal Oncology (ISGIO), hosted by Physicians’ Education Resource, LLC (PER®) presented the latest advances in the field of gastrointestinal cancer research.
Patients with cholangiocarcinoma may derive benefit from treatment with TT-00420, which was recently given a fast track designation by the FDA.
Patients with locally advanced or metastatic biliary tract cancer who received either ramucirumab or merestinib in addition to standard first-line cisplatin and gemcitabine did not experience further survival benefit, although safety remained tolerable.
Patients with advanced biliary tract cancer received a clinically meaningful and statistically significant overall survival benefit after being treated with durvalumab and chemotherapy.
Patients with unresectable hepatocellular carcinoma appeared to benefit from treatment with durvalumab and tremelimumab, according to findings from the phase 3 HIMALAYA trial.
Treatment with nivolumab/ipilimumab and nivolumab/chemotherapy has demonstrated efficacy in unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma, with results from the CheckMate-648 trial leading to the acceptance of the regimens’ applications by the FDA.
A final overall survival analysis found improved results and a tolerable safety profile for patients with advanced IDH1-mutated cholangiocarcinoma who received ivosidenib vs placebo.
Patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib appear to benefit from treatment with pembrolizumab and best supportive care.
Takayuki Yoshino, MD, PhD provides perspective on key issues surrounding therapy selection in gastrointestinal cancers.
Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.